15.1 million Americans are eligible for lung cancer screening, but fewer than 1 million get screened annually with a low-dose CT (that's less than 6%!). DELFI Diagnostics is purpose-built to solve the highest-burden population health issues, starting with lung cancer. Join Victor Velculescu, M.D., Ph.D., DELFI's CEO, as he unveils the company's breakthrough test to help detect cancer at population scale. How? The science of fragmentomics is a remarkable discovery -- when cancer cells die, they shed DNA fragments into the bloodstream that are shaped more haphazardly than those from normal cells. DELFI's advanced machine learning technology identifies these genome-wide DNA fragment patterns and characteristics to spot signs of cancer in their earliest stages. This platform is poised to help drive one of the greatest public health goals of our lifetime--how to make a measurable impact in reducing cancer deaths through accurate, early detection.
Speaker: Victor Velculescu, M.D., Ph.D., CEO and Founder @ DELFI Diagnostics
